Topic:

M&A

Latest Headlines

Latest Headlines

Valeant, Ackman score a chance to force Allergan to an earlier showdown

Don't send out any save-the-dates for that Allergan special shareholder meeting just yet. Valeant has won a request for an expedited trial over the timing of the meeting, a key step in its $50 billion hostile takeover plans.

Medtronic expands hospital services push with $350M acquisition

Medtronic  wants to be known for manufacturing high-quality devices and providing related services as well. To that end, the company today announced the acquisition of privately held Italian company NGC Medical S.p.A.

Allergan sets date for special meeting but vows to keep fighting Valeant buyout

Put it on the calendar: Allergan has scheduled its special shareholder meeting--key to Valeant's takeover attempt--for Dec. 18. But that doesn't mean it won't continue to fight the very idea in court.

It's official: The Pfizer-AstraZeneca deal talk can resume

Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.

Valeant's deal show goes on with $25M dermatology buy

Even a heated takeover battle replete with litigation, a media war, and plenty of name-calling can't grind the Valeant M&A engine to a halt. The company has resumed its skincare buying spree, picking up a dermatology portfolio and an array of specialty products from Valeo Pharma for $25.3 million.

Medtronic adds to neuromodulation biz with $200M Sapiens acquisition

Medtronic today announced the $200 million acquisition of the Netherlands' Sapiens Steering Brain Stimulation to bulk up its neuromodulation offerings.

Lupin took hard look at troubled Wockhardt for possible bid

Nilesh Gupta, managing director of India's Lupin, told Bloomberg that his company gave Wockhardt a financial sizing up recently before deciding it didn't represent a good M&A target.

Scientists develop computer-based quality-control program for cellular engineering

Scientists from three Boston institutions have created CellNet, a computer algorithm to assist scientists in their efforts to engineer specialized cells.

Jumping into global M&A mix key to India growing its pharma industry

India's drug business has taken a big financial hit in the last years as the FDA has stopped some of its top players from shipping drugs to the U.S. But experts still see big potential in the industry, saying it will grow faster than other Indian industries, particularly if players shed their conservative approach and get involved in the global M&A mix that their larger competitors are benefiting from.

No deal: Report asserts that Roche has dropped any plans for Chugai buyout

The news that Roche struck a deal to buy InterMune for $8.3 billion reportedly came at the expense of Chugai's investors.